Professor Matthew Cramp
Profiles

Professor Matthew Cramp

Chair in Hepatology

Peninsula Medical School (Faculty of Health)

Key publications

Key publications are highlighted

Journals
Articles
Dhanda A, Atkinson S, Vergis N, Enki D, Fisher A, Clough R, Cramp M & Thursz M 2020 'Trace element deficiency is highly prevalent and associated with infection and mortality in patients with alcoholic hepatitis' Alimentary Pharmacology & Therapeutics , DOI PEARL
Sánchez-Fueyo A, Whitehouse G, Grageda N, Cramp ME, Lim TY, Romano M, Thirkell S, Lowe K, Fry L & Heward J 2020 'Applicability, safety, and biological activity of regulatory T cell therapy in liver transplantation' American Journal of Transplantation 20, (4) 1125-1136 , DOI
Millson C, Considine A, Cramp ME, Holt A, Hubscher S, Hutchinson J, Jones K, Leithead J, Masson S & Menon K 2020 'Adult liver transplantation: A UK clinical guideline - part 1: pre-operation' Frontline Gastroenterology , DOI
Millson C, Considine A, Cramp ME, Holt A, Hubscher S, Hutchinson J, Jones K, Leithead J, Masson S & Menon K 2020 'Adult liver transplantation: UK clinical guideline - part 2: surgery and post-operation' Frontline Gastroenterology , DOI
Lim TY, McPhail MJ, Shah A, Mahgoub S, Nayagam J, Cramp M, Bernal W, Menon K, Jassem W & Joshi D 2020 'Sequential Cohort Analysis After Liver Transplantation Shows de Novo Extended Release Tacrolimus Is Safe, Efficacious, and Minimizes Renal Dysfunction' Transplantation Direct 6, (2) e528-e528 , DOI
Alsaleh M, Leftley Z, Barbera TA, Koomson LK, Zabron A, Crossey MME, Reeves HL, Cramp M, Ryder S & Greer S 2020 'Characterisation of the Serum Metabolic Signature of Cholangiocarcinoma in a United Kingdom Cohort' Journal of Clinical and Experimental Hepatology 10, (1) 17-29 , DOI
Williams R, Aithal G, Alexander GJ, Allison M, Armstrong I, Aspinall R, Baker A, Batterham R, Brown K & Burton R 2020 'Unacceptable failures: the final report of the Lancet Commission into liver disease in the UK' The Lancet 395, (10219) 226-239 , DOI
Dhanda AD, Yates E, Schewitz-Bowers LP, Lait PJ, Lee RWJ & Cramp ME 2019 'Ex Vivo T Cell Cytokine Expression Predicts Survival in Patients with Severe Alcoholic Hepatitis' Gut and Liver , DOI PEARL
Dhanda AD, Williams EL, Yates E, Lait PJP, Schewitz-Bowers LP, Hegazy D, Cramp ME, Collins PL & Lee RWJ 2019 'Intermediate Monocytes in Acute Alcoholic Hepatitis Are Functionally Activated and Induce IL-17 Expression in CD4+ T Cells' The Journal of Immunology 203, (12) 3190-3198 , DOI
Borgia SM, Dearden J, Yoshida EM, Shafran SD, Brown A, Ben-Ari Z, Cramp ME, Cooper C, Foxton M & Rodriguez CF 2019 'Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis' Journal of Hepatology 71, (4) 660-665 , DOI
Norton BC, Srivastava A, Ramos K, Vine L, Taylor R, Aluvihare V, Heaton N & Cramp ME 2019 'Risk-adjusted survival in liver transplant patients assessed and managed by a non-transplanting centre: South West Liver Unit experience' Frontline Gastroenterology 11, (3) 202-208 , DOI
Lawitz E, Gane E, Feld JJ, Buti M, Foster GR, Rabinovitz M, Burnevich E, Katchman H, Tomasiewicz K & Lahser F 2019 'Efficacy and safety of a two‐drug direct‐acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6' Journal of Viral Hepatitis , DOI
Bennett K, Enki DG, Thursz M, Cramp ME & Dhanda AD 2019 'Systematic review with meta-analysis: high mortality in patients with nonsevere alcoholic hepatitis' Alimentary Pharmacology and Therapeutics , DOI PEARL
Vergara C, Thio CL, Johnson E, Kral AH, O’Brien TR, Goedert JJ, Mangia A, Piazzolla V, Mehta SH & Kirk GD 2019 'Multi-Ancestry Genome-Wide Association Study of Spontaneous Clearance of Hepatitis C Virus' Gastroenterology 156, (5) 1496-1507.e7 , DOI
Williams R, Alexander G, Aspinall R, Batterham R, Bhala N, Bosanquet N, Severi K, Burton A, Burton R & Cramp ME 2018 'Gathering momentum for the way ahead: fifth report of the Lancet Standing Commission on Liver Disease in the UK' The Lancet 392, (10162) 2398-2412 , DOI
Dyson JK, Wong LL, Bigirumurame T, Hirschfield GM, Kendrick S, Oo YH, Lohse AW, Heneghan MA & Jones DEJ 2018 'Inequity of care provision and outcome disparity in autoimmune hepatitis in the United Kingdom' Alimentary Pharmacology & Therapeutics 48, (9) 951-960 , DOI
Carbone M, Nardi A, Flack S, Carpino G, Varvaropoulou N, Gavrila C, Spicer A, Badrock J, Bernuzzi F & Cardinale V 2018 'Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score' The Lancet Gastroenterology & Hepatology 3, (9) 626-634 , DOI
Foster GR, Agarwal K, Cramp ME, Moreea S, Barclay S, Collier J, Brown AS, Ryder SD, Ustianowski A & Forton DM 2018 'Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial' Hepatology 67, (6) 2113-2126 , DOI
Williams R, Alexander G, Armstrong I, Baker A, Bhala N, Camps-Walsh G, Cramp ME, de Lusignan S, Day N & Dhawan A 2017 'Disease burden and costs from excess alcohol consumption, obesity, and viral hepatitis: fourth report of the Lancet Standing Commission on Liver Disease in the UK' The Lancet 391, (10125) 1097-1107 , DOI
Ow MM, Hegazy D, Warshow UM & Cramp ME 2017 'Enhanced natural killer cell activity is found in exposed uninfected recipients of hepatitis C-contaminated blood' Journal of Viral Hepatitis 25, (3) 245-253 , DOI PEARL
Huang H, Duggal P, Thio CL, Latanich R, Goedert JJ, Mangia A, Cox AL, Kirk GD, Mehta S & Aneja J 2017 'Fine-mapping of genetic loci driving spontaneous clearance of hepatitis C virus infection' Scientific Reports 7, Author Site , DOI PEARL
Shawa IT, Sheridan DA, Felmlee DJ & Cramp ME 2017 'Lipid interactions influence hepatitis C virus susceptibility and resistance to infection' Clinical Liver Disease 10, (1) 17-20 , DOI PEARL
Shawa IT, Felmlee DJ, Hegazy D, Sheridan DA & Cramp ME 2017 'Exploration of potential mechanisms of HCV resistance in exposed uninfected intravenous drug users' Journal of Viral Hepatitis , DOI PEARL
Razavi H, Robbins S, Zeuzem S, Negro F, Buti M, Duberg A-S, Roudot-Thoraval F, Craxi A, Manns M & Marinho RT 2017 'Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study' The Lancet Gastroenterology & Hepatology 2, (5) 325-336 , DOI
Williams R, Alexander G, Aspinall R, Bosanquet J, Camps-Walsh G, Cramp M, Day N, Dhawan A, Dillon J & Dyson J 2017 'New metrics for the Lancet Standing Commission on Liver Disease in the UK' The Lancet 389, (10083) 2053-2080 , DOI
Blach S, Zeuzem S, Manns M, Altraif I, Duberg A-S, Muljono DH, Waked I, Alavian SM, Lee M-H & Negro F 2017 'Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study' The Lancet Gastroenterology & Hepatology 2, (3) 161-176 , DOI
Dhanda AD, Sinha A, Hunt V, Saleem S, Cramp ME & Collins PL 2017 'Infection does not increase long-term mortality in patients with acute severe alcoholic hepatitis treated with corticosteroids' World Journal of Gastroenterology 23, (11) 2052-2052 , DOI PEARL
Acevedo JG & Cramp ME 2017 'Hepatorenal syndrome: Update on diagnosis and therapy' World Journal of Hepatology 9, (6) 293-293 , DOI PEARL
Shariff MIF, Kim JU, Ladep NG, Crossey MME, Koomson LK, Zabron A, Reeves H, Cramp M, Ryder S & Greer S 2016 'Urinary Metabotyping of Hepatocellular Carcinoma in a UK Cohort Using Proton Nuclear Magnetic Resonance Spectroscopy' Journal of Clinical and Experimental Hepatology 6, (3) 186-194 , DOI
Swann RE, Mandalou P, Robinson MW, Ow MM, Foung SKH, McLauchlan J, Patel AH & Cramp ME 2016 'Anti-envelope antibody responses in individuals at high risk of hepatitis C virus who resist infection' Journal of Viral Hepatitis 23, (11) 873-880 , DOI PEARL
Vine LJ, Sieberhagen C & Cramp ME 2015 'Diagnosis and management of hepatitis C' British Journal of Hospital Medicine 76, (11) 625-630 , DOI
Williams R, Ashton K, Aspinall R, Bellis MA, Bosanquet J, Cramp ME, Day N, Dhawan A, Dillon J & Dyson J 2015 'Implementation of the Lancet Standing Commission on Liver Disease in the UK' The Lancet 386, (10008) 2098-2111 , DOI
Carbone M, Sharp SJ, Flack S, Paximadas D, Spiess K, Adgey C, Griffiths L, Lim R, Trembling P & Williamson K 2015 'The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis' Hepatology 63, (3) 930-950 , DOI
Cordell HJ, Han Y, Mells GF, Li Y, Hirschfield GM, Greene CS, Xie G, Juran BD, Zhu D & Qian DC 2015 'International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways' Nature Communications 6, (1) , DOI PEARL
Houldsworth A, Metzner M, Hodgkinson A, Shaw S, Kaminski E, Demaine AG & Cramp ME 2015 'Haplotype analysis finds linkage disequilibrium in the IL-12 gene in patients with HCV' J Med Virol 87, (7) 1207-1217 Author Site , DOI
Martin NK, Foster GR, Vilar J, Ryder S, Cramp ME, Gordon F, Dillon JF, Craine N, Busse H & Clements A 2015 'HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact' JOURNAL OF VIRAL HEPATITIS 22, (4) 399-408 Author Site , DOI PEARL
Williams R, Aspinall R, Bellis M, Camps-Walsh G, Cramp M, Dhawan A, Ferguson J, Forton D, Foster G & Gilmore I 2014 'Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis' Lancet 384, (9958) 1953-1997 Author Site , DOI
Williams R, Aspinall R, Bellis M, Camps-Walsh G, Cramp M, Dhawan A, Ferguson J, Forton D, Foster G & Gilmore I 2014 'Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis' Lancet 384, (9958) 1953-1997 Author Site
Ow MMG, Erasmus P, Minto G, Struthers R, Joseph M, Smith A, Warshow UM, Cramp ME & Cross TJS 2014 'Impaired functional capacity in potential liver transplant candidates predicts short-term mortality before transplantation' Liver Transpl 20, (9) 1081-1088 Author Site , DOI
Jothimani D, Cramp ME & Cross TJS 2014 'Role of mycophenolate mofetil for the treatment of autoimmune hepatitis-an observational study' J Clin Exp Hepatol 4, (3) 221-225 Author Site , DOI
Cramp ME, Rosenberg WM, Ryder SD, Blach S & Parkes J 2014 'Modelling the impact of improving screening and treatment of chronic hepatitis C virus infection on future hepatocellular carcinoma rates and liver-related mortality' BMC Gastroenterol 14, Author Site , DOI PEARL
Houldsworth A, Metzner M, Shaw S, Kaminski E, Demaine AG & Cramp ME 2014 'Polymorphic differences in SOD-2 may influence HCV viral clearance' J Med Virol 86, (6) 941-947 Author Site , DOI
Bruggmann P, Berg T, Øvrehus ALH, Moreno C, Brandão Mello CE, Roudot-Thoraval F, Marinho RT, Sherman M, Ryder SD & Sperl J 2014 'Historical epidemiology of hepatitis C virus (HCV) in selected countries' J Viral Hepat 21 Suppl 1, 5-33 Author Site , DOI
Wedemeyer H, Duberg AS, Buti M, Rosenberg WM, Frankova S, Esmat G, Örmeci N, Van Vlierberghe H, Gschwantler M & Akarca U 2014 'Strategies to manage hepatitis C virus (HCV) disease burden' J Viral Hepat 21 Suppl 1, 60-89 Author Site , DOI
Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, Vogel W, Mendes Correa MC, Hézode C & Lázaro P 2014 'The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm' J Viral Hepat 21 Suppl 1, 34-59 Author Site , DOI
Houldsworth A, Metzner MM, Demaine A, Hodgkinson A, Kaminski E & Cramp M 2014 'CD81 sequence and susceptibility to hepatitis C infection' JOURNAL OF MEDICAL VIROLOGY 86, (1) 162-168 Author Site , DOI
Ashraf S, Nitschke K, Warshow UM, Brooks CR, Kim AY, Lauer GM, Hydes TJ, Cramp ME, Alexander G & Little A-M 2013 'Synergism of tapasin and human leukocyte antigens in resolving hepatitis C virus infection' Hepatology 58, (3) 881-889 Author Site , DOI
Duggal P, Thio CL, Wojcik GL, Goedert JJ, Mangia A, Latanich R, Kim AY, Lauer GM, Chung RT & Peters MG 2013 'Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts' Ann Intern Med 158, (4) 235-245 Author Site , DOI
Warshow UM, Riva A, Hegazy D, Thurairajah PH, Kaminski ER, Chokshi S & Cramp ME 2012 'Cytokine profiles in high risk injection drug users suggests innate as opposed to adaptive immunity in apparent resistance to hepatitis C virus infection' J Viral Hepat 19, (7) 501-508 Author Site , DOI
Saunders M, Sieberhagen C, Taylor L, Fry F, McKenna M, Needs S, Chimakurthi R & Cramp M 2012 'POTENTIAL IMPACT OF PROTEASE INHIBITORS IN THE SOUTH WEST PENINSULA HEPATITIS C POPULATION' GUT 61, A140-A141 Author Site , DOI
Tanwar S, Wright M, Foster GR, Ryder SD, Mills PR, Cramp ME, Parkes J & Rosenberg WM 2012 'Randomized clinical trial: a pilot study investigating the safety and effectiveness of an escalating dose of peginterferon α-2a monotherapy for 48 weeks compared with standard clinical care in patients with hepatitis C cirrhosis' Eur J Gastroenterol Hepatol 24, (5) 543-550 Author Site , DOI
Ashraf S, Knapp S, Becford-Tackoir C, Brooks C, Little A-M, Alexander G, Cramp M & Khakoo SI 2011 'OP04 Synergistic influence of tapasin and HLA class I protection against chronic Hepatitis C virus infection' Gut 60, (Suppl 2) A51-A52 , DOI
Warshow U, Sieberhagen C, Hegazy D, Kaminski E, Knapp S, Khakoo S & Cramp ME 2011 'P45 Natural killer cell cytotoxicity is enhanced in injection drug users with apparent resistance to hepatitis C virus infection' Gut 60, (Suppl 2) A21-A22 , DOI
Petrova M, Fung M, Cramp ME, Mitchell JD & Cross TJS 2011 'P80 Patient characteristics and outcomes in a 'Hub and Spoke Model' for liver transplantation provision: The South West Liver Unit/King's College Experience' Gut 60, (Suppl 2) A37-A37 , DOI
Knapp S, Warshow U, Ho KMA, Hegazy D, Little A-M, Fowell A, Alexander G, Thursz M, Cramp M & Khakoo SI 2011 'A Polymorphism in IL28B Distinguishes Exposed, Uninfected Individuals From Spontaneous Resolvers of HCV Infection' GASTROENTEROLOGY 141, (1) 320-U419 Author Site , DOI
Jothimani D, Cramp ME, Mitchell JD & Cross TJS 2011 'Treatment of autoimmune hepatitis: a review of current and evolving therapies' J Gastroenterol Hepatol 26, (4) 619-627 Author Site , DOI
Thurairajah PH, Hegazy D, Demaine A, Kaminski ER & Cramp ME 2011 'Loss of virus-specific T-cell responses in HCV exposed uninfected injection drug users with drug rehabilitation' J Infect Dis 203, (6) 847-853 Author Site , DOI
Knapp S, Warshow U, Hegazy D, Brackenbury L, Guha IN, Fowell A, Little A-M, Alexander GJ, Rosenberg WMC & Cramp ME 2010 'Consistent Beneficial Effects of Killer Cell Immunoglobulin-Like Receptor 2DL3 and Group 1 Human Leukocyte Antigen-C Following Exposure to Hepatitis C Virus' HEPATOLOGY 51, (4) 1168-1175 Author Site , DOI
Rashid M, Mitchell JD, Cramp ME & Cross TJS 2010 'Limitations of the Algorithm for the SAFE Biopsy: A Noninvasive Fibrosis Measure in Chronic Hepatitis C' HEPATOLOGY 51, (1) 354-355 Author Site , DOI
Cross TJS, Mitchell JD & Cramp ME 2009 'Elastography for the non-invasive assessment of liver disease: limitations and future developments' GUT 58, (8) 1171-1172 Author Site
Marcellin P, Reesink H, Berg T, Cramp M, Flisiak R, Van Vlierberghe H, Verloes R, Lenz O, Peeters M & Sekar V 2009 'ANTIVIRAL ACTIVITY AND SAFETY OF TMC435 COMBINED WITH PEGINTERFERON ALPHA-2A AND RIBAVIRIN IN PATIENTS WITH GENOTYPE 1 HEPATITIS C INFECTION WHO FAILED PREVIOUS IFN-BASED THERAPY' JOURNAL OF HEPATOLOGY 50, S385-S385 Author Site , DOI
Hegazy D, Thurairajah P, Metzner M, Houldsworth A, Shaw S, Kaminski E, Demaine AG & Cramp ME 2008 'Interleukin 12B gene polymorphism and apparent resistance to hepatitis C virus infection' Clin Exp Immunol 152, (3) 538-541 Author Site , DOI
Thompson Coon J, Rogers G, Hewson P, Wright D, Anderson R, Jackson S, Ryder S, Cramp M & Stein K 2008 'Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysis' Br J Cancer 98, (7) 1166-1175 Author Site , DOI PEARL
Thompson Coon J, Rogers G, Hewson P, Wright D, Anderson R, Cramp M, Jackson S, Ryder S, Price A & Stein K 2007 'Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis' Health Technol Assess 11, (34) 1-206 Author Site , DOI
Coon JT, Rogers G, Hewson P, Wright D, Anderson R, Cramp M, Jackson S, Ryder S, Price A & Stein K 2007 'Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis' Health Technology Assessment 11, (34) 1-+
Thompson Coon J, Castelnuovo E, Pitt M, Cramp M, Siebert U & Stein K 2006 'Case finding for hepatitis C in primary care: a cost utility analysis' Fam Pract 23, (4) 393-406 Author Site , DOI
Clark SJ, Creighton S, Horner M, Smith HM, Portmann B, Taylor C & Cramp ME 2006 'Reactivation of latent hepatitis B virus infection with HIV-related immunosuppression' Int J STD AIDS 17, (1) 67-69 Author Site , DOI
Castelnuovo E, Thompson-Coon J, Pitt M, Cramp M, Siebert U, Price A & Stein K 2006 'The cost-effectiveness of testing for hepatitis C in former injecting drug users' Health Technology Assessment 10, (32) 1-+
Awasthi AK & Cramp ME 2005 'Hepatic hydrothorax' Br J Hosp Med (Lond) 66, (9) 540-541 Author Site , DOI
Houldsworth A, Metzner M, Rossol S, Shaw S, Kaminski E, Demaine AG & Cramp ME 2005 'Polymorphisms in the IL-12B gene and outcome of HCV infection' J Interferon Cytokine Res 25, (5) 271-276 Author Site , DOI
Ijaz S, Arnold E, Banks M, Bendall RP, Cramp ME, Cunningham R, Dalton HR, Harrison TJ, Hill SF & MacFarlane L 2005 'Non-travel-associated Hepatitis C in England and Wales: Demographic, clinical, and molecular epidemiological characteristics' Journal of Infectious Diseases 192, (7) 1166-1172
Khakoo SI, Thio CL, Martin MP, Brooks CR, Gao X, Astemborski J, Cheng J, Goedert JJ, Vlahov D & Hilgartner M 2004 'HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection' Science 305, (5685) 872-874 Author Site , DOI
Torre F, Cramp M, Owsianka A, Dornan E, Marsden H, Carman W, Williams R & Naoumov NV 2004 'Direct evidence that naturally occurring mutations within hepatitis B core epitope alter CD4+ T-cell reactivity' J Med Virol 72, (3) 370-376 Author Site , DOI
Horne JA, Clements AJ, Drennan P, Stein K & Cramp ME 2004 'Screening for hepatitis C virus in the Dartmoor prison population: an observational study' Journal of Public Health 26, (4) 372-375
Kyrlagkitsis L, Portmann B, Smith H, O'Grady J & Cramp ME 2003 'Liver histology and progression of fibrosis in individuals with chronic hepatitis C and persistently normal ALT' AMERICAN JOURNAL OF GASTROENTEROLOGY 98, (7) 1588-1593 Author Site , DOI
Kyrlagkitsis I, Portmann B, Smith H, O'Grady J & Cramp ME 2003 'Liver histology and progression of fibrosis in individuals with chronic hepatitis C and persistently normal ALT' Am J Gastroenterol 98, (7) 1588-1593 Author Site , DOI
Metzner M, Maulayah P, Benshemesh C & Cramp ME 2003 'Traditional Chinese medicine in the treatment of chronic HCV infection' Gut 52, (5)
Constantini PK, Wawrzynowicz-Syczewska M, Clare M, Boron-Kaczmarska A, McFarlane IG, Cramp ME & Donaldson PT 2002 'Interleukin-1, interleukin-10 and tumour necrosis factor-alpha gene polymorphisms in hepatitis C virus infection: an investigation of the relationships with spontaneous viral clearance and response to alpha-interferon therapy' Liver 22, (5) 404-412 Author Site , DOI
Saravanan R & Cramp ME 2002 'Investigation and treatment of ascites' Clin Med (Lond) 2, (4) 310-313 Author Site , DOI
Katona SJ, Cooper PC, Cramp ME & Kaminski ER 2002 'Re: Whither smooth muscle antibodies in the third millennium?' J Clin Pathol 55, (7) 558-559 Author Site , DOI
Kyrlagkitsis I, Cramp ME, Smith H, Portmann B & O'Grady J 2002 'Acute hepatitis A virus infection: a review of prognostic factors from 25 years experience in a tertiary referral center' Hepatogastroenterology 49, (44) 524-528 Author Site
Clark SJ, Creighton S, Portmann B, Taylor C, Wendon JA & Cramp ME 2002 'Acute liver failure associated with antiretroviral treatment for HIV: a report of six cases' J Hepatol 36, (2) 295-301 Author Site , DOI
Prachalias AA, Pozniak A, Taylor C, Srinivasan P, Muiesan P, Wendon J, Cramp M, Williams R, O'Grady J & Rela M 2001 'Liver transplantation in adults coinfected with HIV' Transplantation 72, (10) 1684-1688 Author Site , DOI
Prachalias AA, Pozniak A, Taylor C, Srinivasan P, Muiesan P, Wendon J, Cramp M, Williams R, O???Grady J & Rela M 2001 'Liver Transplantation in Adults Coinfected With HIV. Transplantation 2001; 72: 1684' Transplantation 72, (10) 1594-1595 , DOI
Kyrlagkitsis I, Portmann B & Cramp ME 2000 'Liver histology and progression of fibrosis in individuals with chronic hepatitis C virus infection and persistently normal ALT' HEPATOLOGY 32, (4) 285A-285A Author Site
Lister RK, Jolles S, Whittaker S, Black C, Forgacs I, Cramp M, Potter M & Rustin MH 2000 'Scleromyxedema: response to high-dose intravenous immunoglobulin (hdIVIg)' J Am Acad Dermatol 43, (2 Pt 2) 403-408 Author Site , DOI
Lister RK, Jolles S, Whittaker S, Black C, Forgacs I, Cramp M, Potter M & Rustin MHA 2000 'Scleromyxedema: Response to high-dose intravenous immunoglobulin (hdIVIg)' Journal of the American Academy of Dermatology 43, (2) 403-408 , DOI
Cramp ME, Rossol S, Chokshi S, Carucci P, Williams R & Naoumov NV 2000 'Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C' Gastroenterology 118, (2) 346-355 Author Site , DOI
Cramp ME 1999 'HBV + HCV = HCC?' Gut 45, (2) 168-169 Author Site , DOI
Cramp ME 1999 'HBV plus HCV=HCC?' GUT 45, (2) 168-169 Author Site , DOI
Datz C, Cramp M, Haas T, Dietze O, Nitschko H, Froesner G, Muss N, Sandhofer F & Vogel W 1999 'The natural course of hepatitis C virus infection 18 years after an epidemic outbreak of non-A, non-B hepatitis in a plasmapheresis centre' Gut 44, (4) 563-567 Author Site , DOI
Cramp ME, Carucci P, Rossol S, Chokshi S, Maertens G, Williams R & Naoumov NV 1999 'Hepatitis C virus (HCV) specific immune responses in anti-HCV positive patients without hepatitis C viraemia' Gut 44, (3) 424-429 Author Site , DOI
Cramp ME, Carucci P, Underhill J, Naoumov NV, Williams R & Donaldson PT 1998 'Association between HLA class II genotype and spontaneous clearance of hepatitis C viraemia' J Hepatol 29, (2) 207-213 Author Site , DOI
CRAMP ME & WILLIAMS R 1997 'Hepatitis in alcohol and drug misusers: practical issues' Addiction Biology 2, (4) 411-420 , DOI
Cramp ME, Grundy HC, Perinpanayagam RM & Barnado DE 1996 'Seroprevalence of hepatitis B and C virus in two institutions caring for mentally handicapped adults' J R Soc Med 89, (7) 401-402 Author Site
Cramp ME, Hing MC, Marriott DJ, Freund J & Cooper DA 1996 'Bile acid malabsorption in HIV infected patients with chronic diarrhoea' Aust N Z J Med 26, (3) 368-371 Author Site , DOI
Inwald D, Nelson M, Cramp M, Francis N & Gazzard B 1994 'Cutaneous manifestations of mycobacterial infection in patients with AIDS' Br J Dermatol 130, (1) 111-114 Author Site , DOI
Cramp ME, Hickey MM & Gazzard MM 1993 'Re-emergence of tuberculosis' BMJ 306, (6882) Author Site , DOI
Grange JM & Yates MD 1993 'Re-emergence of tuberculosis' BMJ 306, (6882) 931-932 , DOI
Collins CD, Blanshard C, Cramp M, Gazzard B & Gleeson JA 1992 'Case report: pneumatosis intestinalis occurring in association with cryptosporidiosis and HIV infection' Clin Radiol 46, (6) 410-411 Author Site , DOI
Tattersall JE, Cramp M, Shannon M, Farrington K & Greenwood RN 1992 'Rapid high-flux dialysis can cure uraemic peripheral neuropathy' Nephrol Dial Transplant 7, (6) 539-540 Author Site
Chapters
Cyril S & Cramp ME 2013 'Clinical and Pathological Features, and Diagnosis' Viral Hepatitis John Wiley & Sons, Ltd 442-449 , DOI
Palmer DH & Cramp ME 2011 'Systemic Therapy for Hepatocellular Carcinoma: Future Directions' Clinical Dilemmas in Primary Liver Cancer Wiley-Blackwell 199-211 , DOI
Conference Papers
Mathurin P, Dufour J-F, Bzowej NH, Shiffman ML, Arterburn S, Nguyen T, Billin A, Chung C, Subramanian M & Myers RP 2018 'Selonsertib in Combination with Prednisolone for the Treatment of Severe Alcoholic Hepatitis: A Phase 2 Randomized Controlled Trial' 1-/-0/19001-/-0/19008A-9A
Haber B, Foster GR, Agarwal K, Cramp ME, Moreea S, Barclay S, Collier J, Brown AS, Ryder SD & Ustianowski A 2017 'Elbasvir/Grazoprevir Plus Sofosbuvir in Treatment-Naive and Treatment-Experienced Cirrhotic Patients with Hepatitis C Virus Genotype 3 Infection Treated for 8, 12 or 16 Weeks: Final Results of the C-ISLE Study' 1-/-0/19001-/-0/1900Elsevier BV S1061-S1061 , DOI
Foster GR, Agarwal K, Cramp M, Moreea S, Barclay ST, Collier J, Brown AS, Ryder SD, Ustianowski A & Forton DM 2016 'C-ISLE: Grazoprevir/Elbasvir plus Sofosbuvir in Treatment-naive and Treatment-experienced HCV GT3 Cirrhotic Patients Treated for 8, 12 or 16 weeks' 1-/-0/19001-/-0/190039A-40A
Agarwal K, Schultz M, Pianko S, Bank L, Collier J, George J, Priest M, Ryder SD, Burman BE & Cheent K 2016 'Sofosbuvir plus Peginterferon plus Ribavirin for 12 Weeks in Genotype 3 HCV Infected Patients and Treatment-Experienced Cirrhotic Patients with Genotype 2 HCV Who Did Not Achieve SVR after 16 or 24 Weeks of Sofosbuvir plus Ribavirin' 1-/-0/19001-/-0/1900455A-456A
Ahmed A, Dhanda A, Hegazy D, Felmlee D, Sheridan D & Cramp M 2016 'Sustained viral clearance of HCV with DAA treatment is associated with restoration of effector T cell phenotype' 1-/-0/19001-/-0/1900745A-745A
Jothimani D, Govil S, Vij M, Sheridan D, Cramp M & Rela M 2016 'Predicting Fatty Liver Disease in Healthy Potential Liver Donors' 1-/-0/19001-/-0/1900Elsevier BV S479-S479 , DOI
Asselah T, Shafran S, Bourgeois S, Lai C-L, Cramp M, Mathurin P, Willems B, Nguyen MH, Davis MN & Huang KC 2016 'SOFOSBUVIR/VELPATASVIR FIXED DOSE COMBINATION FOR 12 WEEKS IN HCV INFECTED PATIENTS PREVIOUSLY TREATED WITH PLACEBO: RESULTS OF THE DEFERRED TREATMENT STUDY (GS-US-342-1446 STUDY)' 1-/-0/19001-/-0/1900S827-S828
Mandalou P, Robinson MW, Felmlee D, Sieberhagen C, Mindos T, Hegazy D, MacLaughlan J & Cramp ME 2015 'PTH-100 A comparative gene expression study between individuals with apparent resistance, spontaneous clearance, or chronic infection from hcv' 1-/-0/19001-/-0/1900BMJ A452.1-A452 , DOI
Norton BC, Adebayo D, Ramos K, Smith A & Cramp M 2015 'PTH-124 Liver transplant outcomes in patients with care devolved to a non-transplanting centre: south west liver unit experience' 1-/-0/19001-/-0/1900BMJ A462.2-A463 , DOI
Dhar A, Tschotazis E, Brown R, Manousou P, Millson C, Aldersley M, Forbes S, Aggarwal K, Gera A & Cramp M 2015 'LP11 : Warfarin anticoagulation for liver fibrosis in patients transplanted for hepatitis C (WAFT-C): results at one year' 1-/-0/19001-/-0/1900Elsevier BV S268-S269 , DOI
Ow M, Hegazy D & Cramp ME 2014 'P210 ALTERATIONS IN CXCR3/CXCL10 BUT NOT CCR5 IN HCV ARE ASSOCIATED WITH VIRAL INHIBITION WITH INTERFERON-FREE DIRECT ACTING ANTIVIRAL THERAPY' 1-/-0/19001-/-0/1900Elsevier BV S136-S136 , DOI
Rosenberg WM, Cramp M, Davis M, Parkes J, Ryder S, Razavi H & Hindman S 2014 'P790 REDUCING THE DISEASE BURDEN OF CHRONIC HEPATITIS C VIRUS (HCV) INFECTION IN ENGLAND' 1-/-0/19001-/-0/1900Elsevier BV S333-S334 , DOI
Ow MM, Hegazy D, Warshow U & Cramp ME 2014 'High-Level Resistance to Hepatitis C - A Possible Role for Innate Immunity' 1-/-0/19001-/-0/19001064A-1064A
Mandalou P, Swann R, Patel AH & Cramp ME 2014 'Neutralising anti-envelope antibodies in uninfected individuals that are repeatedly exposed to HCV' 1-/-0/19001-/-0/19001057A-1057A
Martin NK, Vickerman P, Clements A, Cramp M, De Angeles D, Dillon JF, Fahey S, Foster GR, Goldberg DJ & Gordon F 2013 'ARE CURRENT TREATMENT RATES SUFFICIENT TO REDUCE HCV PREVALENCE AMONG PEOPLE WHO INJECT DRUGS? MODEL PROJECTIONS IN SEVEN UK SETTINGS' 1-/-0/19001-/-0/1900S356-S356 , DOI
Joseph M, Erasmus P, Minto G, Mitchell J, Cramp M & Cross TJ 2013 'THE USE OF CARDIOPULMONARY EXERCISE TESTING IN PREDICTING PRE- AND POST-OPERATIVE MORTALITY IN LIVER TRANSPLANT CANDIDATES' 1-/-0/19001-/-0/1900S412-S412 , DOI
Petrova M, Fung M & Cramp M 2012 'HPS AND INTRAPULMONARY VASCULAR SHUNTS IN LIVER TRANSPLANT CANDIDATES' 1-/-0/19001-/-0/1900S254-S254 , DOI
Ashraf S, Knapp S, Becford-Tackoir C, Brooks C, Little A-M, Alexander G, Cramp M & Khakoo SI 2011 'Synergistic influence of tapasin and HLA class I protection against chronic hepatitis C virus infection' 1-/-0/19001-/-0/1900173-173
Warshow U, Sieberhagen C, Hegazy DM, Kaminski E, Knapp S, Khakoo S & Cramp ME 2011 'NATURAL KILLER CELL CYTOTOXICITY IS ENHANCED IN INJECTION DRUG USERS WITH APPARENT RESISTANCE TO HEPATITIS C VIRUS INFECTION' 1-/-0/19001-/-0/19001322A-1322A
Knapp S, Ho KM, Warshow U, Heqazy D, Little A-M, Alexander G, Thursz M, Cramp ME & Khakoo SI 2011 'ABSENCE OF IL-28B PROTECTION IN INDIVIDUALS EXPOSED TO HEPATITIS C VIRUS DEMONSTRATES DISCRETE GENETIC PATHWAYS FOR PROTECTION AGAINST CHRONIC HCV INFECTION' 1-/-0/19001-/-0/1900S38-S39 , DOI
Tanwar S, Wright M, Foster GR, Ryder SD, Mills PR, Cramp ME, Parkes J & Rosenberg WM 2010 'INDIVIDUALIZED CONCENTRATION MONITORED HIGH DOSE RIBAVIRIN IN COMBINATION WITH PEGINTERFERON TO HEPATITIS C GENOTYPE 1 PATIENTS WITH PREVIOUS NONRESPONSE' 1-/-0/19001-/-0/1900710A-711A
Tanwar S, Wright M, Foster GR, Ryder SD, Mills PR, Cramp ME, Parkes J & Rosenberg WM 2010 'PACIFIC: A PHASE III, RANDOMIZED, MULTICENTER, DOSE ESCALATION, EFFICACY AND SAFETY STUDY EXAMINING THE EFFECTS OF TREATMENT WITH PEGINTERFERON ALFA-2A IN PATIENTS WITH CHILD'S A OR B CIRRHOSIS IN CHRONIC HEPATITIS C VIRUS INFECTION' 1-/-0/19001-/-0/1900710A-710A
Sieberhagen C, Brown ASM, Demuth DG, Livingstone JA & Cramp ME 2010 'PREDICTORS OF HEPATITIS C TREATMENT OUTCOME IN GENOTYPE 1 PATIENTS IN A "REAL WORLD" SETTING' 1-/-0/19001-/-0/1900A77-A77 , DOI
Warshow U, Knapp S, Brackenbury LS, Hegazy D, Thurairajah PH, Khakoo S & Cramp ME 2009 'ASSOCIATION OF HLA AND NK CELL INHIBITORY RECEPTOR WITH APPARENT RESISTANCE TO HEPATITIS C INFECTION' 1-/-0/19001-/-0/1900386A-386A
Hegazy D, Edwards P, Warshow U & Cramp ME 2009 'CELLULAR DISTRIBUTION OF CLAUDIN 1 IN LIVER TISSUE IN HEPATITIS C AND OTHER LIVER DISEASES' 1-/-0/19001-/-0/1900950A-950A
Warshow U, Riva A, Thurairajah PH, Hegazy D, Chokshi S & Cramp ME 2009 'CYTOKINE PROFILES IN HCV EXPOSED BUT UNINFECTED CASES WITH APPARENT RESISTANCE TO HCV INFECTION' 1-/-0/19001-/-0/1900936A-936A
Thurairajah P, Warshow U, Demaine A, Kaminski E, Hegazy D & Cramp ME 2009 'LONGITUDINAL ANALYSIS OF HEPATITIS C VIRUS SPECIFIC T CELL RESPONSES IN EXPOSED UNINFECTED INTRAVENOUS DRUG USERS' 1-/-0/19001-/-0/1900A17-A17
Thurairajah P, Warshow U, Demaine A, Kaminski E, Hegazy D & Cramp ME 2009 'LONGITUDINAL ANALYSIS OF HCV SPECIFIC T-CELL RESPONSES IN EXPOSED UNINFECTED INTRAVENOUS DRUG USERS' 1-/-0/19001-/-0/1900S326-S326 , DOI
Thurairajah PH, Hegazy D, Chokshi S, Shaw S, Demaine A, Kaminski ER, Naoumov NV & Cramp ME 2008 'Hepatitis C virus (HCV)--specific T cell responses in injection drug users with apparent resistance to HCV infection' United States 1-/-0/19001-/-0/19001749-1755 , DOI
Barnardo AT, Walters L, Cramp M & Mitchell J 2008 'Audit of management of alcohol withdrawal at derriford hospital' 1-/-0/19001-/-0/1900A72-A72
Barnardo AT, Warshow U, Mitchell J & Cramp M 2008 'Mycophenolate mofetil in patients with refractory autoimmune hepatitis' 1-/-0/19001-/-0/1900A71-A72
Thurairajah PH, Hegazy DM, Richardon SJ, Demaine AG, Kaminski ER & Cramp ME 2007 'HCV-specific cellular immune responses in intravenous drug users without HCV infection' 1-/-0/19001-/-0/1900240A-241A
Hegazy DM, Thurairajah PH, Metzner M, Houldsworth A, Kaminski E, Demaine A & Cramp ME 2007 'Interleukin 12B gene polymorphism and apparent resistance to HCV infection' 1-/-0/19001-/-0/1900890A-891A
Thurairajah PH, Hegazy D, Kaminski E, Demaine A & Cramp ME 2007 'Single nucleotide polymorphism of the SRB1 gene and susceptibility to HCV infection' 1-/-0/19001-/-0/1900A134-A135
Thurairajah PH, Hegazy D, Kaminski E, Demaine A, Cunningham R & Cramp ME 2006 'Late spontaneous clearance of hepatitis C' 1-/-0/19001-/-0/1900A43-A43
Houldsworth A, Metzner M, Demaine AG, Kaminski E & Cramp ME 2005 'CD81 sequence and susceptibility to HCV infection' 1-/-0/19001-/-0/1900A47-A47
Metzner M, Houldsworth A, Demaine AG, Kaminski E & Cramp ME 2005 'HCV-specific cellular immune responses in subjects exposed to but uninfected by HCV' 1-/-0/19001-/-0/1900A6-A7
Metzner MK, Houldsworth A, Demaine A, Kaminski E & Cramp ME 2005 'HCV-specific cellular immune responses in subjects exposed, but uninfected by HCV' 1-/-0/19001-/-0/1900A712-A712 PEARL
Beckly JB, Jackson S, Cramp ME & Beckly DE 2004 'Endoscopic sphincterotomy is sufficient treatment for most post cholecystectomy bile leaks' 1-/-0/19001-/-0/1900A44-A44
Houldsworth A, Metzner M, Rossol S, Kaminski E, Demaine AG & Cramp ME 2003 'IL-12 gene polymorphism and outcome of HCV infection' 1-/-0/19001-/-0/1900356A-356A
Kyrlagkitsis I, Metzner M, Smith H, Depla E, Sablon E & Cramp ME 2003 'Specific antibody titres vary over time in individuals with chronic HCV infection and persistently negative HCV RNA' 1-/-0/19001-/-0/1900
Kyrlagkitsis I, Metzner MK, Smith H, Depla E, Sablon E & Cramp ME 2002 'Specific antibody titres vary over time in individuals with chronic HCV infection and persistently negative HCV RNA' 1-/-0/19001-/-0/1900552A-552A
Metzner MK, Maulayah P, Benshemesh C & Cramp ME 2002 'Traditional Chinese medicine in the treatment of chronic HCV infection' 1-/-0/19001-/-0/1900569A-569A
Clark SJ, Creighton S, Horner M, Portmann BC, Cramp M & Taylor C 2000 'Reactivation of latent hepatitis B virus infection with HIV related immunosuppression' 1-/-0/19001-/-0/1900454A-454A
Clare MA, Portmann BC & Cramp ME 1999 'The association of the Arg25Pro polymorphism in the TGF beta 1 gene with fibrosis in chronic hepatitis C patients' 1-/-0/19001-/-0/1900331A-331A
Cramp ME, Maertens G, O'Grady J & Rossol S 1999 'HCV-specific immune responses in HCV exposed but uninfected cases' 1-/-0/19001-/-0/1900A97-A97
Cramp ME & Rossol S 1998 'HCV-specific T helper cell responses in HCV exposed but uninfected cases' 1-/-0/19001-/-0/1900200A-200A
Cramp ME, Rossol S, Chokshi S, Carucci P, Williams R & Naoumov NV 1998 'HLA class III and class II alleles in hepatitis C virus infection and outcome' 1-/-0/19001-/-0/1900159-160
Cramp ME, Rossol S, Chokshi S, Carucci P, Williams R & Naoumov NV 1998 'Interferon induced virus specific T helper cell responses are associated with viral clearance in chronic HCV infection' 1-/-0/19001-/-0/1900155-155
Torre F, Cramp M, Owsianka A, Carman W, Williams R & Naoumov NV 1998 'Mutations within a promiscuous immunodominant epitope in hepatitis B core protein and their effect on T helper cell response' 1-/-0/19001-/-0/1900156-157
Cramp ME, Rossol S, Carucci P, Williams R, Naoumov NV & Donaldson PT 1998 'The influence of the HLA class II allele DQB1*0301 on HCV specific T helper cell responses' 1-/-0/19001-/-0/1900A21-A21
Cramp ME, Rossol S, Chokshi S, Carucci P, Williams R & Naoumov NV 1997 'Interferon induced virus specific T helper cell responses are associated with viral clearance in chronic HCV infection' 1-/-0/19001-/-0/19001111-1111
Rossol S, Cramp ME, Carucci P, Singer MV, Williams R & Naoumov NV 1997 'Reduced production of interleukin-12 by PBMC from patients with chronic hepatitis C' 1-/-0/19001-/-0/19001121-1121
Torre F, Cramp ME, Owsianka A, Carman W, Williams R & Naoumov NV 1997 'T helper cell response to mutations within a promiscuous immunodominant epitope in acute and chronic hepatitis B' 1-/-0/19001-/-0/19001953-1953
Bernal W, Cramp M, Underhill JA, Carucci P & Donaldson PT 1997 'Tumor necrosis factor gene polymorphisms in hepatitis C virus infection' 1-/-0/19001-/-0/19001413-1413
Cramp ME, Chokshi S, Tzampouras N, Torre F, Williams R & Naoumov NV 1997 'Beneficial in vitro effects of tucaresol on the immune response to hepatitis C virus' 1-/-0/19001-/-0/1900TH119-TH119
Cramp ME, Carucci P, Chokshi S, Rossol S, Donaldson PT, Williams R & Naoumov NV 1996 'A multispecific T lymphocyte response to hepatitis C virus proteins occurs in patients with viral clearance and persists many years after exposure' 1-/-0/19001-/-0/1900503-503
Cramp ME, Carucci P, Donaldson PT, Underhill J, Tibbs C, Naoumov NV & Williams R 1996 'Evidence that HLA class II genotype may be associated with clearance of hepatitis C virus' 1-/-0/19001-/-0/190099-99
Reports
Castelnuovo E, Thompson-Coon J, Pitt M, Cramp M, Siebert U, Price A & Stein K 2006 The cost-effectiveness of testing for hepatitis C in former injecting drug users. Author Site , DOI
Posters
Yates E, Cramp M & Dhanda A Yates E, Cramp M & Dhanda A 0 'A NOVEL FUNCTIONAL BIOASSAY PREDICTS 90-DAY SURVIVAL IN PATIENTS WITH SEVERE ALCOHOLIC HEPATITIS' 01/01/190001/01/1900Author Site , DOI PEARL
Foster GR, Agarwal K, Cramp ME, Moreea S, Barclay S, Collier J, Brown AS, Ryder SD, Ustianowski A & Forton DM Foster GR, Agarwal K, Cramp ME, Moreea S, Barclay S, Collier J, Brown AS, Ryder SD, Ustianowski A & Forton DM 0 'Elbasvir/grazoprevir plus sofosbuvir in treatment-naive and treatment-experienced cirrhotic patients with hepatitis C virus genotype 3 infection treated for 8, 12, or 16 weeks: final results of the C-ISLE study' 01/01/190001/01/1900, DOI
Dhanda A, Williams E, Yates E, Collins P, Lee R & Cramp M Dhanda A, Williams E, Yates E, Collins P, Lee R & Cramp M 0 'Intermediate (CD14++CD16+) monocytes from patients with acute severe alcoholic hepatitis are activated and functionally similar to classical (CD14++CD16−) monocytes' 01/01/190001/01/1900, DOI
Foster G, Agarwal K, Cramp ME, Moreea S, Barclay S, Collier J, Brown AS, Ryder SD, Ustianowski A & Forton DM Foster G, Agarwal K, Cramp ME, Moreea S, Barclay S, Collier J, Brown AS, Ryder SD, Ustianowski A & Forton DM 0 'Successful treatment of patients with HCV GT3 infection and cirrhosis with elbasvir/grazoprevir plus sofosbuvir does not correct insulin resistance by 12 weeks post-treatment' 01/01/190001/01/1900, DOI